News | April 01, 2009

Texas Hospital First in World to Treat Heart Patient with New Adult Stem Cell Therapy

April 1, 2009 - On March 30, the Heart Hospital of Austin, TX became the first hospital in the world to treat a patient enrolled in a groundbreaking Phase II study designed to test the effectiveness and safety of administering adult stem cells intravenously to repair damaged heart tissue after a heart attack.
Cardiologist Roger Gammon, M.D. treated a 58-year-old Central Texas man with the experimental adult stem cell treatment, just days after the patient’s first heart attack.
"We are excited to be the first to treat a patient in this groundbreaking study and to lead the way in this important research," stated Dr. Gammon.
Prochymal is being evaluated for its ability to treat heart damage caused by a heart attack. The active ingredient in the new treatment is adult Mesenchymal Stem Cells (MSCs). The cells in the drug are from normal, healthy adult volunteer donors and are not from a fetus, embryo or animal. MSCs reportedly have the ability to develop into other types of cells and generate new tissue, including heart muscle. Prochymal is a product of Osiris Therapeutics Inc.
"There's a lot of enthusiasm in the cardiovascular community about the potential of stem cell therapies for treating heart disease. Earlier studies have established confidence in the safety of the therapy, but more research is needed to study its effectiveness," said Dr. Gammon.
In this prospective, double-blind, placebo-controlled Phase II study, Heart Hospital of Austin and Austin Heart researchers will study patients to determine the effectiveness and safety of Prochymal for treating heart damage resulting from a heart attack. Heart Hospital of Austin is one of approximately 40 institutions in the United States and Canada participating in the study. Patients who participate in the study must receive the treatment within seven days of a heart attack. The stem cell treatment is administered intravenously and typically takes less than an hour to complete.
Prochymal is currently an investigational therapy and is not yet approved by the Food and Drug Administration.
For more information: www.hearthospitalofaustin.com

Related Content

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Cardiovascular Clinical Studies | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init